SPRO (Spero Therapeutics) Cyclically Adjusted FCF per Share: $-2.58 (As of Mar. 2026)


SPRO Spero Therapeutics Inc SPRO
55 GF Score
Price $2.26
GF Value $1.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics Cyclically Adjusted FCF per Share?

Spero Therapeutics SPRO +11.88% 55 Cyclically Adjusted FCF per Share is $-2.58 as of Mar. 2026. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Spero Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.277. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-2.58 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-06-28), Spero Therapeutics's current stock price is $2.26. Spero Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-2.58. Spero Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Spero Therapeutics  (NAS:SPRO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Spero Therapeutics Cyclically Adjusted FCF per Share Related Terms


Spero Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Cyclically Adjusted FCF per Share Chart

Spero Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Spero Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -2.58

SPRO vs ORMP, PLYX, HRTX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Spero Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spero Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


SPRO
55GF Score
Spero Therapeutics Inc SPRO
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spero Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.277/330.2130*330.2130
=0.277

Current CPI (Mar. 2026) = 330.2130.

Spero Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.000 236.525 0.000
201609 -1.020 241.428 -1.395
201612 -1.433 241.432 -1.960
201703 -1.057 243.801 -1.432
201706 -1.344 244.955 -1.812
201709 -0.785 246.819 -1.050
201712 -0.887 246.524 -1.188
201803 -0.832 249.554 -1.101
201806 -0.601 251.989 -0.788
201809 -0.316 252.439 -0.413
201812 -0.761 251.233 -1.000
201903 -0.639 254.202 -0.830
201906 -0.688 256.143 -0.887
201909 -0.519 256.759 -0.667
201912 -0.918 256.974 -1.180
202003 -1.197 258.115 -1.531
202006 -1.207 257.797 -1.546
202009 -0.972 260.280 -1.233
202012 -0.598 260.474 -0.758
202103 -0.526 264.877 -0.656
202106 -0.558 271.696 -0.678
202109 -0.154 274.310 -0.185
202112 -0.846 278.802 -1.002
202203 -0.866 287.504 -0.995
202206 -0.698 296.311 -0.778
202209 -0.027 296.808 -0.030
202212 0.911 296.797 1.014
202303 -0.245 301.836 -0.268
202306 -0.353 305.109 -0.382
202309 0.302 307.789 0.324
202312 -0.323 306.746 -0.348
202403 0.111 312.332 0.117
202406 -0.347 314.175 -0.365
202409 0.236 315.301 0.247
202412 -0.429 315.605 -0.449
202503 -0.072 319.799 -0.074
202506 -0.316 322.561 -0.323
202509 0.310 324.800 0.315
202512 -0.122 324.054 -0.124
202603 0.277 330.213 0.277

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-2.58 mean?
Spero Therapeutics (SPRO) has a Cyclically Adjusted FCF per Share of $-2.58 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Spero Therapeutics and its competitors.
Is Spero Therapeutics' Cyclically Adjusted FCF per Share too high?
Spero Therapeutics' current Cyclically Adjusted FCF per Share is $-2.58. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Cyclically Adjusted FCF per Share compare to ORMP and PLYX?
Spero Therapeutics' Cyclically Adjusted FCF per Share of $-2.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current Cyclically Adjusted FCF per Share is $-2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $2.26 — trading 113.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-2.58. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Cyclically Adjusted FCF per Share is $-2.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.26 is trading 113.2% above its estimated GF Value™ of $1.06. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

  • Cyclically Adjusted FCF per Share: $-2.58
  • GF Value™: $1.06 vs. price of $2.26 (113.2% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spero Therapeutics Business Description

Other Exchanges 2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score

Get the complete analysis for SPRO

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price
$1.06
GF Value